Krishna Institute of Medical Sciences Limited has announced a scheduled analyst and institutional investor meeting as part of the DAM Capital Hospitals & Diagnostics conference. The meeting represents part of the company's ongoing investor engagement activities in compliance with regulatory requirements.

Meeting Details

The healthcare provider has disclosed the following details for the upcoming investor interaction:

Regulatory Compliance

The announcement has been made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed companies to disclose material events and information that could impact investor decisions.

Krishna Institute of Medical Sciences has specifically stated that no unpublished price sensitive information will be shared during the meeting. This commitment ensures compliance with insider trading regulations and maintains fair disclosure practices.

Schedule Flexibility

The company has noted that the meeting schedule remains subject to change due to any exigencies that may arise. This standard disclaimer provides operational flexibility while maintaining transparency with stakeholders about potential modifications to the planned timeline.

The disclosure was signed by Nagajayanthi J.R, Company Secretary & Compliance Officer, on March 16, 2026, demonstrating the company's commitment to timely regulatory reporting and investor communication.

Krishna Institute of Medical Sciences Limited has announced a scheduled analyst and institutional investor meeting with Aberdeen, set to take place on March 18, 2026. The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Meeting Details

The upcoming investor engagement has been structured as a virtual meeting to facilitate broader participation and accessibility.

Regulatory Compliance

The company has made this announcement pursuant to SEBI's disclosure requirements for listed entities. Krishna Institute of Medical Sciences has specifically noted that no unpublished price sensitive information will be shared during the scheduled meeting, ensuring compliance with insider trading regulations.

Schedule Flexibility

The healthcare services provider has indicated that the meeting schedule remains subject to change due to any exigencies that may arise. This standard disclaimer provides flexibility while maintaining transparency with stakeholders about potential scheduling adjustments.

The disclosure was signed by Nagajayanthi J.R, who serves as the Company Secretary and Compliance Officer for Krishna Institute of Medical Sciences Limited. The formal communication was digitally signed and submitted to both the Bombay Stock Exchange and National Stock Exchange on March 14, 2026.